To test this hypothesis, erythrocytes from PNH patients (PNH1–PNH4) were treated with ABO-matched sera containing CPV-104, sd-FH, pegcetacoplan, or eculizumab. The gene discussed is FH; the disease is paroxysmal nocturnal hemoglobinuria.